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Summary 
Elevated levels of immunoglobulin (Ig) E are associated with bronchial asthma, a disease  char- 
acterized by eosinophilic inflammation of the airways.  Activation of antigen-specific T  helper 
(Th) 2 cells in the lung with the subsequent release ofinterleukin (IL) 4 and IL-5 is believed to 
play an important role in the pathogenesis of this disease. In this study, we have used a non- 
anaphylactogenic anti-mouse-IgE antibody to investigate the relationship between IgE, airway 
eosinophil infiltration, and the production ofTh2 cytokines. Immunization of mice with house 
dust mite antigen increased serum levels of IgE and IgG. Antigen challenge of immunized but 
not control mice induced an infiltration ofeosinophils in the bronchoalveolar lavage associated 
with the production of IL-4 and IL-5 from lung purified Thyl.2  + cells activated through the 
CD3-T cell receptor complex. Administration of the anti-IgE monoclonal antibody (mAb) 6 h 
before antigen challenge neutralized serum IgE but not IgG and inhibited the recruitment of 
eosinophils into the lungs and the production of IL-4 and IL-5 but not interferon ~/. Studies 
performed using an anti-CD23 mAb, CD23 deficient and mast cell deficient mice suggest that 
anti-IgE  mAb  suppresses  eosinophil  infiltration and  Th2  cytokine production by inhibiting 
IgE-CD23-facilitated antigen presentation to T  cells. Our results demonstrate that IgE-depen- 
dent mechanisms are important in the induction ofa Th2 immune response and the subsequent 
infiltration ofeosinophils into the airways.  Neutralization oflgE by, for example, non-anaphy- 
lactogenic anti-IgE mAbs may provide a novel therapeutic approach to the treatment of allergic 
airway disease. 
B 
ronchial asthma  is  characterized pathologically by an 
infiltration of eosinophils into  the  airway submucosa 
(1). Eosinophil activation results in the secretion of an array 
of highly charged cytotoxic cationic proteins such as major 
basic  protein, and is believed to play a  central role in the 
etiology of this disease  by inducing damage to the airway 
epithelium (2),  activation of sensory C-fibers  (3),  and the 
generation of proinflammatory mediators (4).  The mecha- 
nisms by which these cells are recruited into the airways af- 
ter antigen provocation, however, are less clear. Studies per- 
formed in experimental animals have suggested that CD4 + 
T  cells of the Th2 phenotype play a critical role in the de- 
velopment of eosinophil accumulation, mediated by their 
ability to secrete IL-5 (5-7). Th2 cells also  produce IL-4, 
which at least in murine systems is essential  in instructing B 
cells to switch to IgE production (8).  It has been demon- 
strated both in vitro (9-11) and in vivo (5, 12) that IL-4 is 
also  required for antigen naive CD4 +  T  cells  to become 
committed to  the  Th2 phenotype.  More  recently, it has 
been demonstrated that a similar Th2 profile exists  in the 
lungs  of individuals with  allergic airway disease  (13,  14), 
further supporting the  hypothesis that Th2-derived cyto- 
kines play an important role in the initiation and perhaps 
also in the maintainance of bronchial asthma. 
In addition to eosinophilic inflammation of the airways, 
elevated levels of IgE in both the serum and bronchoalveo- 
lar lavage  (BAL) 1 fluid are  also  associated with bronchial 
asthma  (15-17).  IgE-dependent  mast  cell  activation  is  a 
central mechanism in antigen-induced bronchoconstriction 
mediated largely through the production of histamine and 
LTD4 (18).  Although IgE has  been implicated in the in- 
1Abbreviations used in this paper: BAL, bronchoalveolar  lavage; DMA, dust 
mite antigen; M, mouse. 
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and the development ofa Th2 immune response and eosin- 
ophilic inflammation of the airways is at present unknown. 
To investigate this further, we have used a non-anaphylac- 
togenic rat anti-murine IgE antibody (termed 1-5) that does 
not  induce  activation of mast  cells and  basophils  (19).  In 
this study,  we  show  that  IgE-dependent mechanisms play 
an important role in Th2  cytokine production and in the 
development  of eosinophilic inflammation  of the  airways 
and discuss the implication and therapeutic potential of lgE 
inhibition for the treatment of bronchial asthma. 
Materials  and Methods 
Non-anaphylactogenic Anti-IgE  1-5 mAb 
The rat IgG1 anti-mouse IgE 1-5 antibody is lgE isotype spe- 
cific and reacts with free IgE but does not recognize IgE bound to 
mast cells (19).  This antibody presumably recognizes an epitope 
within the FceRI-binding region. As a result of this binding spec- 
ificity, the antibody 1-5 does not induce histamine release from 
IgE-sensitized rat  basophilic leukemia  cells,  and  based  on  this 
property is termed non-anaphylactogenic. 
Quantification of Eosinophil Recruitment to the Lung 
BALB/C  mice  (20-25  g)  were  immunized intraperitoneally 
with 2 ~g of  house dust mite antigen (DMA) (Greer Laboratories, 
Lenoir, NC) in 0.2 ml of alum (Serva, Heidelberg, Germany) on 
day 0 and boosted with DMA/alum on day 14. Non-immunized 
control mice received two injections of alum alone. 7 d after the 
last  immunization,  animals  were  anesthetized  with  isofluorane 
and challenged by the intranasal route with 100 p~g of DMA (in a 
volume of 50 b~l). Mice were injected intraperitoneally with 200 
p~g of anti-IgE 1-5 mAb or matched isotype IgG control 6 h be- 
fore the booster injection or airway challenge. 72 h after antigen 
inhalation,  mice  were  anesthetized with  urethane,  the  trachea 
cannulated, and BAL performed by five repeated lavages with 0.3 
ml  of saline injected into  the  lungs via the  trachea.  Total cell 
counts were performed, cytospin preparations were prepared, and 
a differential count of 200 cells was performed. In addition, 72 h 
after allergen challenge, blood was  taken  from  the  descending 
aorta, and serum levels of total IgE and IgG were measured by 
ELISA as described below. 
Experiments  were  also  performed  in  mast  cell-deficient 
WBB6F1/J-W/W  v and normal congenic mice as described above 
to determine the possible involvement of mast cell activation in 
the recruitment of eosinophils to the lung. Likewise, to investi- 
gate the possible contribution of IgE bound to the low-a~nity 
IgE receptor (CD23), we administered a neutralizing anti-CD23 
antibody (20,  21)  (B3B4,  1 mg i.p.) 24  h  before challenge and 
performed a BAL 72 h  later. Finally, to determine whether the 
anti-IgE  1-5  mAb inhibits eosinophil infiltration via a  CD23- 
dependent mechanism, we administered the anti-IgE 1-5 mAb 6 h 
before antigen provocation in  CD23  wild-type or CD23-defi- 
cient mice (22). 
Determination of Serum IgE and IgG 1 
Mouse lgG1 and IgE were determined by ELISA as described 
previously (23) with the following alterations. Briefly, microtiter 
plates were  coated with  rat  anti-mouse  (M)  IgG1  LOMG1-2 
(Zymed 04-6100) and rat anti-M IgE 4B3-39 (Ciba-Geigy Ltd.), 
respectively. After incubation  with  dilutions of serum  samples, 
bound  mouse  Ig was  detected with  biotinylated rat  anti-M  K 
R33-18-12 (kindly provided by Prof. G. H~immerling,  Krebsfor- 
schungszentrum, Heidelberg, Germany) and rat anti-M lgE 3-11 
(Ciba-Geigy Ltd.), respectively. Antibodies 4B3-39 and 3-11 rec- 
ognize different epitopes on the IgE molecule than the non-ana- 
phylactogenic anti-IgE antibody 1-5 without inducing steric hin- 
drance. Thus,  the combination of anti-M IgE antibodies chosen 
for this assay resulted in a highly sensitive and isotype-specific de- 
tection of mouse IgE, which is not affected by an even large ex- 
cess of anti-IgE 1-5 mAb in the serum sample. 
In  Vitro Experiments 
Purification of Lung T Cells.  To analyze the lung T  cell cyto- 
kine profile, experiments were performed in BALB/c mice 72 h 
after  antigen  challenge  as  decribed previously  (5).  Mice  were 
treated with anti-IgE 1-5 mAb or matched isotype control anti- 
body 6 h before the booster injection or airway challenge. After 
the five repeated lavages  for assessment  of the inflammatory cell 
infiltrate, a further five lavages were performed with 1 ml of ster- 
ile PBS to remove remaining resident alveolar macrophages. The 
lungs were then perfused via the right ventricle with 5 ml of PBS 
containing 100 U/ml of heparin to remove any blood and intra- 
vascular leukocytes. The  lungs were  then  removed and placed 
into DMEM containing 10% FCS, 2-ME (50  IxM), L-glutamine 
(2 mM), sodium pyruvate (1  mM), Hepes (10 raM), and genta- 
mycin (50 Ixg/ml). The lungs were then gently homogenized, the 
cell suspension was filtered through a 70-1xM filter, and lympho- 
cytes were enriched over a single step Ficoll gradient. B cells were 
depleted from  the  cell  suspension  using  magnetic  sheep  anti- 
mouse  Ig beads  (Dynabeads;  Dynal AS,  Oslo,  Norway).  Cells 
were then labeled with Thy-1.2-FITC (PharMingen, San Diego, 
CA)  and purified with a flow cytometer (Becton Dickinson, & 
Co., Mountain View, CA) as described previously (6). In all ex- 
periments, purity was >99.5% Thy1.2 +. 
Cell Culture.  Lung Thyl.2 + cells were plated at a concentra- 
tion of 2  ￿  105 in 96-well microtiter plates coated with an anti- 
CD3 antibody (2C11, 50/xg/ml). Cells were cultured for 72 h in 
the presence of human IL-2 (200 U/ml). Supernatants were har- 
vested, and cytokine production was determined by ELISA as de- 
scribed elsewhere (12).  The limits of detection were as follows: 
IL-4, 0.5 U/ml; IL-5, 100 U/ml; IFN-y, 10 U/ml. 
Results 
Anti-IgE 1-5 mAb Neutralizes Serum IgE and Inhibits Eosin- 
ophil Infiltration.  Antigen provocation of immunized mice 
resulted in a sdective eosinophil infiltration in the airways 
(nonimmunized,  0.13,  -  0.09  eosinophils/ml  ￿  105; im- 
munized, 7.5  •  2.0 eosinophils/ml ￿  105) associated with 
elevated levels of IgE  (non-immunized,  <200  ng/ml; im- 
munized,  11.6  -  3  txg/ml) and IgG (non-in~unized,  665 
•  119  ~g/ml;  immunized,  3,418  •  919  Ixg/ml).  Treat- 
ment of mice with the anti-IgE 1-5 mAb (200 ~g) 6 h  be- 
fore antigen challenge neutralized serum IgE by >80% (2.1 
•  0.5 I~g/ml, n =  6, P  <0.001;  Fig. 1 A) and inhibited the 
recruitment  of eosinophils  into  the  lungs  (2.24  •  0.86 
cells~m1  ￿  105,  P  <0.02;  Fig.  1  B).  In contrast,  anti-IgE 
mAb 1-5 did not reduce serum IgG levels (3,783  •  981  ~g/ 
ml, P  >0.05). 
Anti-IgE  1-5 mAb Inhibits the Production of Th2 Cytokines 
from Lung T  Cells.  Consistent  with  our  previous  results 
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serum  IgE or  (B)  antigen-induced  eosinophil infiltration in 
mice immunized  with  DMA.  Levels of IgE and eosinophil 
number of nonimmunized mice (open bars) is shown for com- 
parison. Anti-IgE 1-5  mAb  (black bars) or isotype matched 
control Ig (grey bars)  was administered 6 h before antigen chal- 
lenge. Data are shown as the mean + SEM of five to seven an- 
imals in each group. Statistical  significance  was determined by 
Student's t test, and a value ofP <0.05 (*) was considered sig- 
nificant. 
(5), airway antigen challenge of immunized mice results in 
the  production  of Th2  cytokines  upon  reactivation  via 
cross-linking of the CD3-TCK  complex. In contrast, acti- 
vation of Thyl.2 +  cells from the lungs of non-immunized 
mice produced IFN-~ and no IL-4 or IL-5. Administration 
of anti-IgE 1-5 mAb to immunized mice 6  h  before aller- 
gen provocation inhibited the production of IL-4 by 95% 
(control Ig, 66  +  6 U/ml; anti-IgE, 3  +  1 U/rnl) and IL-5 
by 97%  (control  Ig, 2,500  •  145  U/m];  anti-IgE,  267  + 
61  U/m/) but did not affect IFN-~ production (control Ig, 
64  +  8  U/m];  anti-IgE, 84  •  3  U/ml)  (Fig. 2). 
Anti-IgE  1-5 mAb Mediated  Suppression  of Antigen-induced 
Eosinophil Infiltration,  Th2 Cytokine Production,  and Neutraliza- 
tion of Serum IgE Can Be Temporally Dissociated.  To  under- 
stand more fully the  relationship between  free serum  IgE, 
eosinophil  infiltration,  and  the  production  of Th2  cyto- 
kines,  we  administered the  anti-IgE  1-5  mAb,  either be- 
fore  the  booster injection  (i.e.,  10  d  before  challenge)  or 
24 h  before, 30 rain before, or 24 h  after challenge. At each 
time point of antibody administration, there was a  compa- 
rable neutralization of free IgE in  the serum.  This was not 
due to an inhibition of the read-out assay by anti-IgE  1-5 
mAb  present  in  the  serum  sample,  as  we  used  an  IgE 
ELISA that is not affected by the presence of the anti-IgE 
1-5  mAb.  The  ability of anti-IgE  1-5  mAb  to  neutralize 
IgE was  temporally dissociated from the inhibition of eo- 
sinophi/infiltration, in that anti-IgE  1-5 mAb only inhib- 
ited eosinophil infiltration when  given within 24  h  of the 
antigen provocation,  and not before the booster injection 
or 24 h  after the  antigen challenge  (Fig. 3).  Likewise, ad~ 
ministration of anti-IgE 1-5 mAb failed to inhibit the pro- 
duction  of IL-4  and  IL-5  when  administered  before  the 
booster injection  compared  with  animals  treated  with  an 
isotype-matched control antibody (Fig. 4).  These observa- 
tions suggest that inhibition of antigen-induced eosinophil 
infiltration and  Th2  cytokine production by anti-IgE  l-5 
mAb cannot be simply explained by a neutralization of free 
serum IgE. 
IgE-Dependent  Triggering of the FcERI on Mast Cells Cannot 
Account for the Effect  of Anti-IgE  I-5  mAb  on Eosinophil Re- 
cruitment.  To  explore the mechanism of action by which 
anti-IgE  1-5  mAb  inhibits  Th2  cytokine production  and 
eosinophil recruitment, we next performed experiments in 
mast  cell-deficient  WBB6F1/J-W/W v  and  normal  con- 
genic mice.  There was no significant difference in the de- 
gree  of eosinophil infiltration in  mast  cell-deficient mice 
compared with congenic normal control mice (n =  6, P  = 
0.41;  Fig.  5),  suggesting that inhibition of IgE-dependent 
triggering of the  FceRI  on  mast  cells cannot  account  for 
the inhibitory effect ofanti-IgE 1-5 mAb on eosinophil in- 
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Figure 2.  The effect of anti-IgE 1-5 mAb on production of 
cytokines from FACS|  Thyl.2  + lung cells obtained from 
nonimmunized mice (open  bars), immunized mice receiving con- 
trol isotype Ig (grey bars), and immunized mice receiving anti- 
Ig,  E  (black bars). The  anti-lgE  1-5  mAb  (or isotype-matched 
control antibody) was administered 6 h before DMA challenge 
as illustrated. Data are shown as the mean •  SEM of three indi- 
vidual cultures obtained from the pooled  lungs of five to  six 
mice in each group. Figure 3.  Temporal dissociation between  the effect of 
anti-lgE 1-5 mAb on levels of (A) serum IgE and (B) anti- 
gen-induced  eosinophil  infiltration.  The  anti-lgE  1-5 
mAb  (black bars) was administered 10 d, 24 h, 6 h, or 30 
rain before antigen challenge or 24 h after antigen chal- 
lenge. Data for the isotype-matched control Ig (grey bars) 
are shown for comparison. Data are shown as the mean + 
SEM of four to five animals in each group. Statistical  sig- 
nificance was determined by Student's t test, and a value of 
P <0.05 (*) was considered significant. 
filtration and Th2  cytokine production.  It is thus  possible 
that anti-IgE mediates its effect through  inhibition of IgE 
binding to CD23. 
Anti--IgE mAb  1-5 Inhibits Eosinophil Infiltration via a CD23- 
dependent Mechanism.  To  determine  the  involvement  of 
an  IgE-CD23--dependent  mechanism  in  antigen-induced 
eosinophil infiltration, we either administered an anti-CD23 
mAb (B3B4)  (20,  21)  or used mice in which  the gene for 
CD23  was  deleted  by  homologous  recombination  (22). 
Administration ofa mAb against CD23 24 h  before antigen 
provocation inhibited the  recruitment  of eosinophils into 
the lungs by 60%  (nonirnmunized,  0.1  _  0.1  eosinophils/ 
ml ￿  10  s, n =  4; immunized +  control Ig, 7.5  -+ 2.6 eosin- 
ophils/ml ￿  10  s, n  =  4; immunized  +  anti-CD23,  3.2  + 
0.5  eosinophils/ml ￿  10  s,  n  =  5;  P  <0.05;  Fig. 6).  Simi- 
larly, CD23-deficient  mice had an  impaired ability to  re- 
cruit eosinophils into the lung (Fig. 7).  However, whereas 
anti-IgE 1-5 mAb inhibited eosinophil recruitment in CD23 
wild-type  mice,  there  was  no  additional  suppression  of 
eosinophil infiltration by anti-IgE 1-5 mAb in CD23-defi- 
cient mice (control wild-type mice, 7.1  +-  1.0 eosinophils/ 
ml  ￿  10 s,  n  =  6;  control  wild-type  +  anti-IgE-treated 
mice,  1.19  +  1.0 eosinophils/ml ￿  105,  n  =  4, P  =  0.01; 
CD23-deficient mice, 0.53  +  0.20  eosinophils/ml ￿  105, 
n =  5; CD23 deficient +  anti-IgE 1-5-treated mice, 0.59  +- 
0.34 eosinophils/ml ￿  105,  n  =  5,  P  =  0.9; Fig. 7). These 
observations suggest that CD23-dependent mechanisms are 
involved  in  the  recruitment  of eosinophils  into  the  lung 
and  that  anti-IgE  1-5  mAb  affects  the  interaction  of IgE 
with CD23 for the suppression of eosinophil recruitment. 
Discussion 
Elevated levels of serum IgE and the presence of eosino- 
phils in the lung submucosa have long been associated with 
bronchial asthma  (1,  16,  17,  24).  However,  it is unknown 
whether  antigen-induced  eosinophil  accumulation  in  the 
lungs is dependent on IgE or whether they are independent 
manifestations of the  allergic status.  In this study, we  for- 
mally demonstrate  using  an  anti-IgE mAb  that  IgE  is re- 
quired for the recruitment of eosinophils into the lung after 
antigen provocation. 
Figure 4.  The effect ofanti-IgE 1-5 mAb on production of 
cytokines from  FACS|  Thyl.2  + lung  cells obtained 
from nonimmunized mice (open bars), immunized mice receiv- 
ing control isotype Ig (grey bars), and immunized mice receiv- 
ing anti-IgE  (black bars). The anti-lgE 1-5 mAb or isotype- 
matched control Ig was administered during immunization as 
illustrated. Data are shown as the mean +  SEM of three indi- 
vidual cultures obtained from the pooled lungs of five to six 
mice in each group. 
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cient mice (WI3B6FJJ-W/W")  (grey bars) or congenic normal mice (open 
bars). Data are expressed as the mean +  SEM of six mice in each group. 
Statistical significance was determined by Student's t test, and a value of 
P <0,05 (*) was considered  significant. 
The  anti-IgE  mAb  used  in  this  study  has  the  unique 
property that it neutralizes  free serum IgE, binds  to  mem- 
brane  IgE  +  B  cells,  and  thus  inhibits  IgE  production  by 
these  cells.  However,  this  mAb  fails  to  bind  to  IgE  on 
Fc~IKI on mast cells and basophils (19; Heusser,  C., manu- 
script  in  preparation).  Based on these  properties,  the  anti- 
IgE mAb does not induce mast cell/basophil activation and 
degranulation and, as such,  is designated non-anaphylacto- 
genic. Furthermore,  this anti-IgE mAb inhibits IgE binding 
to a  mast cell line  and thus  competes with  FcdKI for IgE 
binding (19). Therefore, the epitope of this antibody is pre- 
sumably located within  the  FcelKI binding region on IgE, 
which is mapped to the ~-CH3 domain. 
Administration  of anti-IgE  1-5  mAb neutralized  serum 
IgE by >80%, without affecting serum levels oflgG. These 
observations  are  in  agreement  with  our  previous  results 
demonstrating that administration  of anti-IgE 1-5 mAb in- 
hibited the production of antigen-specific  IgE but not IgG 
responses  (19).  In  the  present  series  of experiments,  it  is 
shown that anti-IgE 1-5 mAb, but not the isotype-matched 
control antibody,  inhibits  the  accumulation  of eosinophils 
into the lungs, which leads us to conclude that IgE depen- 
dent mechanisms play an important role in the recruitment 
of eosinophils into the lungs. 
Figure  6.  Inhibition of antigen-induced eosinophil recruitment by a 
CD23 mAb. Immunized mice were treated with anti-CD23 mAb (black 
bars) or isotype matched control lg (grey bars), 24 h before antigen chal- 
lenge. Data are expressed as the mean -+ SEM of six mice in each group. 
Statistical significance was determined by Student's t test, and a value of 
P <0.05 (") was considered significant. 
Figure 7.  Antigen-induced eosinophil infiltratmn in CD23 wild-type 
or CD23-deficient mice. 6 h before antigen challenge, mice were treated 
with the anti-IgE (black bars) or matched isotype control Ig (grey bars). 
Data are expressed as the mean +- SEM of four to five mice in each 
group. Statistical significance was determined by Student's t test, and a 
value of P <0.05 (*) was considered significant. 
The precise mechanism(s) underlying the requirement of 
lgE in the recruitment of eosinophils to the lungs is at present 
unclear. However, previous studies have demonstrated that 
IgE-dependent mast  cell  activation  in  vivo leads  to bron- 
choconstriction  (25)  and  increased  airway  responsiveness 
(26).  lgE-mediated  mast  cell  triggering has also been sug- 
gested to play a role in other aspects of the allergic response 
by inducing leukocyte infiltration  (27)  and increasing col- 
lagen gene expression (28), which are in part dependent on 
TNF-et  production  (27,  28).  Mast  cell  activation  has  also 
been  shown  to  result  in  the  secretion  of IL-3,  GM-CSF, 
IL-4, and  IL-5  (29-31),  which  could account for the  in- 
duction of eosinophil infiltration.  However, under our ex- 
perimental  conditions,  it is  unlikely  that mast  cells  are in- 
volved in  the  recruitment  of eosinophils  to  the  lung and 
that anti-lgE  1-5 mAb inhibits  eosinophit accumulafon via 
IgE bound  to  FcelKI on these  cells,  for two reasons.  First, 
anti-lgE  1-5 mAb, while effectively preventing IgE binding 
to a  mast cell line  (32),  would  not be  expected  to  readily 
displace high affinity prebound IgE, particularly in view of 
the relatively short time required to inhibit eosinophil infil- 
tration.  Second,  in  agreement  with  previous  studies,  we 
also report that mast cell-deficient  mice develop a  normal 
lung  eosinophilic  response  to  antigen  provocation  (33), 
suggesting that IgE-dependent mast cell degranulation is not 
a  critical  event  in  the  recruitment  of eosinophils  into  the 
lung  and  cannot  explain  the  e~cacy of the  anti-IgE  1-5 
mAb. 
We and others have previously demonstrated that the re- 
cruitment  of eosinophils into  the  airways is  dependent  on 
the  activation  of the  Th2 subset  of CD4 +  T  cells  and the 
subsequent secretion of IL-5 (5, 6).  Therefore, we next in- 
vestigated whether anti-IgE  1-5 mAb can inhibit the pro- 
duction ofTh2 cytokines. Our results demonstrate that ad- 
ministration of the anti-IgE 1-5 mAb inhibited the ex vivo 
production  of IL-4 and  IL-5  from lung  T  cells  activated 
through  the  CD3-TC1K  complex.  In  contrast,  there  was 
no inhibition  in the production of IFN %  demonstrating a 
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IgE is not only required for the recruitment of eosinophils 
into the lung, but IgE-dependent mechanisms are also re- 
quired for the  activation  of T  cells  and  subsequent  Th2 
cytokine secretion. As  eosinophil infiltration is dependent 
on IL-5 secreted by CD4 + T  cells,  we conclude that the 
inhibition  of Th2  cytokine  production  by  anti-IgE  1-5 
mAb  is  the  mechanism  by  which  this  antibody  inhibits 
eosinophil infiltration of the lung. 
Recent in vitro studies have demonstrated that antigen- 
IgE complexes, but not antigen-IgG complexes bound to 
CD23,  allows B  cells  to  facihtate antigen presentation to 
antigen-specific T  cells,  resulting in a greatly amplified T 
cell response (34, 35). The concept oflgE-dependent anti- 
gen affinity focusing has more recently been demonstrated 
in vivo, using anti-CD23  mAbs  (36,  37)  and CD23  defi- 
cient  mice  (38).  We  therefore investigated  whether  IgE 
bound to low affinity Fc~RII is involved in the recruitment 
of eosinophils into the lungs after antigen provocation. Ad- 
ministration of anti-CD23 mAb inhibited antigen-induced 
lung eosinophil'accumulation by >60%,  raising the possi- 
bility that anti-IgE  mAb inhibits  eosinophil accumulation 
thus  impairing  IgE  antigen  focusing  to  antigen-specific 
CD4 + T  cells in the lung, resulting in a failure of the Th2 
cells to proliferate and secrete IL-5. This concept is further 
supported  by  the  demonstration  that  eosinophil  recruit- 
ment was  attenuated in  CD23-deficient mice. Moreover, 
anti-IgE 1-5 mAb failed to inhibit residual eosinophil infil- 
tration in these mice. These observations may explain the 
recent demonstration that CD23-deficient mice fail to de- 
velop  an  increase  in  airway  responsiveness  after  antigen 
challenge (39).  However, whether CD23 § positive B  cells 
(20) and/or dendritic cells (21) mediate antigen focusing to 
lung Th2 cells remains to be determined. 
There was, however, a temporal dissociation between the 
ability of the  anti-IgE  1-5  mAb  to  neutralize serum  IgE 
and to inhibit eosinophil accumulation and the production 
of Th2 cytokines. Administration of anti-IgE 1-5 mAb dur- 
ing immunization effectively neutralized serum IgE but failed 
to  suppress  eosinophil infiltration and Th2  cytokine pro- 
duction, supporting the hypothesis that the mode of action 
of the anti-IgE 1-5 mAb is not simply related to neutraliza- 
tion of free serum IgE and may reflect the requirement for 
a critical concentration of anti-IgE 1-5 mAb for optimal in- 
hibition of IgE-CD23 interactions. 
Chimerized (40) or reshaped (41) anti-human IgE mAbs 
have also been reported as potential antiallergic  compounds. 
Interestingly, one of these mAbs  (40) was selected on the 
basis of its inability to induce histamine release from baso- 
phils and was shown to inhibit IgE-CD23 interactions, simi- 
lar to the murine anti-IgE 1-5 mAb. In contrast,  the reshaped 
anti-IgE mAb was selected to compete with IgE for bind- 
ing to  the  FceR.I and mimic  Fc~tkI  binding activity and 
may not interfere with  IgE-CD23.  Based on  the present 
data, our prediction would be that an anti-IgE mAb that in- 
terferes with IgE binding to both Fc~tks (I and II) would be 
more effective in the treatment of  allergic disorders. 
The  IgE-CD23-mediated  antigen  presentation,  which 
apparently leads  to an induction of Th2 cytokine produc- 
tion,  could represent a positive feedback loop responsible 
for amplifying an  allergic  asthmatic  response.  Our results 
open up the possibility that inhibition of IL-4 production 
by anti-IgE  mAb  could prevent such  an  amplification of 
the  immune  response by preventing the  switch  of virgin 
IgM +  B cells to IgE production and the subsequent "arm- 
ing" with IgE of FceRI and FceRlI on mast cells and APC, 
respectively.  Moreover,  as  IL-4  is  required  not  only  to 
drive CD4 + T  cells to a Th2 phenotype, but may also be 
required to sustain  a Th2 immune response (42),  treatment 
with anti-IgE mAb may also prevent this positive feedback 
mechanism.  However,  it  still  remains  to  be  determined 
whether  inhibition  of eosinophil  infiltration by  anti-IgE 
1-5 mAb is also associated with an attenuation of allergen- 
induced airway hyperreactivity. 
In conclusion, IgE plays a critical role in the production 
of Th2 cytokines and in the development of eosinophil re- 
cruitment into  the  airways after antigen provocation. Al- 
though the precise mechanisms underlying this observation 
remain to be fully elucidated, there is evidence to suggest 
that this occurs via an inhibition of CD23/IgE-enhanced 
antigen  processing and  presentation  to  CD4 +  T  cells  in 
lungs and subsequent activation and Th2 cytokine produc- 
tion.  Our data suggest that inhibition of IgE represents a 
novel approach for the treatment of asthma,  not  only by 
preventing IgE binding to mast cells (resulting in inhibition 
of bronchoconstriction), but also by inhibiting the activa- 
tion of Th2 cytokine-producing cells and the recruitment 
of eosinophils into the lungs. Finally, these results highlight 
the  therapeutic potential of anti-IgE  mAbs  for the  treat- 
ment of allergic disorders such as bronchial asthma. 
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